VistaGen Therapeutics

OverviewSuggest Edit

VistaGen Therapeutics is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders. The Company's product AV-101, an NMDA receptor glycine-binding site antagonist, is a new generation oral antidepressant drug candidate in Phase 2 development, initially for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard FDA-approved antidepressant therapies. 

TypePublic
Founded1998
HQSouth San Francisco, CA, US
Websitevistagen.com

Latest Updates

Employees (est.) (Jun 2019)9
Revenue (FY, 2018)$0(-100%)
Share Price (Jun 2021)$2.8(-1%)
Cybersecurity ratingCMore

Key People/Management at VistaGen Therapeutics

Shawn K. Singh

Shawn K. Singh

Chief Executive Officer and Director
Jon S. Saxe

Jon S. Saxe

Chairman of the Board
H. Ralph Snodgrass

H. Ralph Snodgrass

Founder, President, Chief Scientific Officer and Director
Jerry Gin

Jerry Gin

Director
Ann Cunningham

Ann Cunningham

Director
Joanne Curley

Joanne Curley

Director
Show more

VistaGen Therapeutics Office Locations

VistaGen Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
343 Allerton Ave
Show all (1)

VistaGen Therapeutics Financials and Metrics

VistaGen Therapeutics Revenue

USD

Revenue (Q3, 2021)

313.6k

Net income (Q3, 2021)

(5.3m)

EBIT (Q3, 2021)

(5.3m)

Market capitalization (11-Jun-2021)

532.6m

Closing stock price (11-Jun-2021)

2.8

Cash (31-Dec-2020)

104.3m

EV

432.0m
VistaGen Therapeutics's current market capitalization is $532.6 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.3m200.4k1.3m

General and administrative expense

5.0m3.6m2.5m4.3m13.9m6.3m6.4m7.5m7.4m

R&D expense

5.4m3.4m2.5m2.4m3.9m5.2m7.8m17.1m13.4m

Operating expense total

10.4m7.0m5.0m6.8m17.9m11.5m14.2m24.6m20.8m
Quarterly
USDQ2, 2011Q3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q3, 2021

Revenue

554.6k2.4k200.4k1.3m313.6k

General and administrative expense

1.1m1.5m1.1m604.6k545.9k897.0k797.2k556.1k671.3k1.4m3.7m1.3m1.1m1.5m2.3m1.2m2.6m1.3m1.5m2.2m1.9m1.9m1.1m2.9m1.4m2.1m

R&D expense

1.0m1.3m866.3k695.5k669.3k551.3k473.6k557.6k445.4k372.6k1.7m806.3k825.7k1.6m1.6m1.1m2.4m1.6m2.7m5.3m5.3m4.3m4.2m3.0m1.7m3.5m

Operating expense total

2.2m2.9m1.9m1.3m1.2m1.4m1.3m1.1m1.1m1.8m5.4m2.1m2.0m3.1m3.9m2.3m5.0m2.9m4.2m7.4m7.2m6.2m5.4m6.0m3.1m5.6m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

81.0k638.1k70.0k428.5k2.9m10.4m13.1m1.4m

Accounts Receivable

106.2k300.0k

Prepaid Expenses

50.9k33.7k40.5k35.7k426.8k644.8k250.9k225.1k

Current Assets

238.1k671.8k40.5k105.7k855.3k3.4m11.0m13.7m1.6m
Quarterly
USDQ2, 2011Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q3, 2021

Cash

942.1k166.4k31.7k24.2k89.8k6.5k20.7k400.7k13.2k121.0k694.0k1.2m8.5m6.3m4.4m1.6m1.8m13.0m7.2m7.8m6.3m8.3m4.1m1.1m1.5m104.3m

Accounts Receivable

148.5k7.8k

Prepaid Expenses

485.8k107.7k511.2k82.8k134.9k147.5k70.6k62.3k1.5m1.1m728.3k498.0k563.3k940.4k617.3k648.0k853.8k482.6k604.5k319.0k633.0k547.5k

Current Assets

1.6m281.9k542.9k107.0k224.7k154.0k91.3k554.6k189.9k75.5k1.6m1.8m1.9m8.6m6.9m5.8m2.1m2.3m14.0m7.8m8.5m7.1m8.8m4.7m1.4m2.2m105.0m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(12.2m)(12.9m)(3.0m)(13.9m)(47.2m)(10.3m)(14.3m)(24.6m)(20.8m)

Depreciation and Amortization

45.6k33.8k54.6k59.1k53.5k54.9k80.7k91.2k103.1k

Accounts Payable

2.8m1.4m2.2m2.0m(547.2k)(451.7k)541.7k1.3m(390.7k)

Cash From Operating Activities

(3.6m)(3.5m)(2.1m)(2.8m)(4.8m)(7.3m)(9.1m)(14.5m)(15.8m)
Quarterly
USDQ2, 2011Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q3, 2021

Net Income

(2.4m)(9.2m)(1.8m)(9.1m)185.7k(1.3m)(1.1m)(4.6m)(6.6m)(7.7m)(29.5m)(36.6m)(38.7m)(2.0m)(5.1m)(7.7m)(2.3m)(7.3m)(10.3m)(4.2m)(11.6m)(18.9m)(6.2m)(11.5m)(17.5m)(3.1m)(11.7m)

Depreciation and Amortization

10.8k33.5k5.9k21.0k12.2k25.8k40.2k13.1k26.2k39.2k14.5k28.9k40.8k13.3k26.0k37.6k23.6k46.2k65.3k15.0k37.9k64.8k26.2k52.1k77.6k25.4k77.3k

Accounts Payable

583.9k1.3m816.1k1.0m616.3k1.2m1.7m1.7m291.0k(51.9k)(264.5k)(473.5k)466.4k(41.8k)171.7k(212.3k)511.8k40.2k924.5k(178.9k)(434.4k)(1.1m)

Cash From Operating Activities

(1.1m)(2.8m)(296.2k)(2.5m)(731.8k)(1.3m)(1.7m)(1.0m)(1.5m)(1.9m)(823.3k)(2.3m)(3.5m)(1.7m)(3.9m)(6.0m)(2.1m)(4.0m)(6.5m)(3.1m)(7.1m)(11.0m)(4.8m)(8.9m)(13.2m)(2.8m)(6.8m)
USDQ2, 2011

Financial Leverage

-0.2 x
Show all financial metrics

VistaGen Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

VistaGen Therapeutics Online and Social Media Presence

Embed Graph

VistaGen Therapeutics News and Updates

VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder

PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder

VistaGen Therapeutics to Present at Two Investor Conferences in June

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“…

VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer

Ann Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global life cycle product management expertise for many successful branded product campaigns for large pharmaceutical companies Ann Cunningham has a proven pharmaceutical commerc…

VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other…

VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021

Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD)

VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervou…
Show more

VistaGen Therapeutics Blogs

VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors

Dr. Curley brings extensive pharmaceutical industry experience in product development, commercialization and operations as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaG…

VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study

PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and …

VistaGen Therapeutics Announces Proposed Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous sy…

VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression

Previously completed Phase 2A clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration SOUTH SAN FRANCISCO, Calif., Dec. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a bioph…

VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Medicine

Dr. Monti developed the innovative scientific platform that enabled the early research and development of VistaGen's PH94B and PH10, intranasal neuroactive steroid drug candidates (pherines) with potential for the rapid-onset treatment of anxiety and depression disorders, respectively SOUTH SAN F…

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress

Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021 Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid…
Show more

VistaGen Therapeutics Frequently Asked Questions

  • When was VistaGen Therapeutics founded?

    VistaGen Therapeutics was founded in 1998.

  • Who are VistaGen Therapeutics key executives?

    VistaGen Therapeutics's key executives are Shawn K. Singh, Jon S. Saxe and H. Ralph Snodgrass.

  • How many employees does VistaGen Therapeutics have?

    VistaGen Therapeutics has 9 employees.

  • Who are VistaGen Therapeutics competitors?

    Competitors of VistaGen Therapeutics include Suven Life Sciences, Tiaki Therapeutics and Neuraly.

  • Where is VistaGen Therapeutics headquarters?

    VistaGen Therapeutics headquarters is located at 343 Allerton Ave, South San Francisco.

  • Where are VistaGen Therapeutics offices?

    VistaGen Therapeutics has an office in South San Francisco.

  • How many offices does VistaGen Therapeutics have?

    VistaGen Therapeutics has 1 office.